Akers announced that it has added six distributors to sell Particle ImmunoFiltration Assay (PIFA Heparin/PF4) in nine countries. PIFA Heparin/PF4 Rapid Assay is the only approved rapid test (both in the U.S. and Europe) that quickly determines if a patient being treated with the blood thinner heparin may be developing a drug allergy or heparin-induced thrombocytopenia (HIT).
In the U.S. alone, approximately 12 million patients are exposed to heparin annually and 1% to 5% of those patients receive HIT diagnosis. Akers estimates that an average U.S. hospital can save well over $1 million patients annually by using this rapid test. Most recently, Akers signed a distribution agreement with ADS Inc. to supply its rapid diagnostic kits to the U.S. government agencies and departments.
The recent distribution agreement with LabPro d.o.o expands Akers’ footprint into Serbia, Montenegro, Macedonia, and Bosnia and Herzegovina. The company also partnered with Pathway Diagnostics for Great Britain; ACCUSCIENCE Ireland for Ireland and Northern Ireland and AVL Sofia Ltd for Bulgaria.
(Source: nasdaq.com)
